Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration: What is the Evidence?

ISSN： 1170-229X

Source： Drugs & Aging, Vol.26, Iss.4, 2009-05, pp. : 295-320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration: What are the Implications of CATT for Routine Management?

By Ziemssen Focke Sobolewska Bianka

Drugs & Aging, Vol. 28, Iss. 11, 2011-11 ,pp. : 853-865

Adis International

Access to resources Recommend Favorite

Verteporfin worth it for age-related macular degeneration in the UK?

Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Off-Label Use of Atypical Antipsychotics: Cause for Concern?

By McKean Andrew

CNS Drugs, Vol. 26, Iss. 5, 2012-05 ,pp. : 383-390

Adis International

Access to resources Recommend Favorite

Vitamins and Cognition: What is the Evidence?

By Kennedy David O. Haskell Crystal F.

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 1957-1971

Adis International

Access to resources Recommend Favorite

By Lacour M.

Drugs & Aging, Vol. 19, Iss. 2, 2002-02 ,pp. : 101-133

Adis International

Access to resources Recommend Favorite